IntrinsicIntrinsic

INTEL CORP

INTC
🏢 Semiconductors & Related Devices

Business Operations Summary

Intel Corporation is a global designer and manufacturer of semiconductor products, with its CPUs and other semiconductor solutions incorporated in computing and related end products and services utilized globally by consumers, enterprises, governments and educational organizations. The company operates as a U.S.-based integrated design manufacturer, or IDM, and is the only company undertaking research, design and development of leading-edge and next generation semiconductor manufacturing technologies and high-volume manufacturing of logic semiconductors utilizing leading-edge nodes in the U.S. The semiconductor industry in 2025 experienced momentum driven by significantly increased compute demand, particularly for GPU systems, driven by generative AI workloads; an expansion in the types of AI workloads; a PC market driven by user refreshes resulting from expanding AI capabilities, end-of-support for Windows 10 and aging devices from the COVID era; and increased demand for secure and geographically diversified supply chains in a period of increased geopolitical tensions.

Intel's primary competitors include AMD, which like Intel designs processors based on the x86 architecture, and companies that design processors based on the ARM architecture, such as Apple with its M series products, Qualcomm with its Snapdragon products and MediaTek with its Kompanio products. In the data center market, competitors include AMD, NVIDIA, and companies developing their own custom silicon, including many hyperscalers such as Amazon, Google, Meta and Microsoft. In the foundry business, Intel's primary competitor in leading-edge semiconductor process technology is TSMC, which holds a leading position in manufacturing at scale for the most advanced nodes, and Intel also competes directly with Samsung in this market. The company's three largest customers accounted for 43% of net revenue in 2025, 45% in 2024 and 40% in 2023.

Intel generates revenue through the design, development, marketing, sale, support and servicing of CPUs and related semiconductor products, with substantially all of its revenue derived from product sales. The company's customers primarily include OEMs, ODMs, CSPs, and other manufacturers and service providers, and it markets and sells products through a combination of direct sales and indirect channels including distributors, resellers, retailers and OEM partners. The company's business is organized into three reportable segments: Client Computing Group (CCG), Data Center and AI (DCAI), and Intel Foundry, with an "all other" category that includes Mobileye, IMS Nanofabrication, and historical results from divested businesses including Altera.

The CCG segment delivers platforms and processors that power PCs and edge devices, with key product offerings including Intel Core and Intel Core Ultra client CPUs, discrete client GPUs under the Intel Arc brand, edge computing solutions, and connectivity products. CCG revenue was $32.228 billion in 2025, $33.346 billion in 2024, and $32.305 billion in 2023, with operating income of $9.317 billion , $11.594 billion , and $10.128 billion respectively. The DCAI segment delivers workload-optimized solutions based upon the x86 architecture for data centers, including CPUs, AI accelerators, NICs, IPUs, and custom ASICs, with key products including Intel Xeon server processors, discrete GPUs, and networking products. DCAI revenue was $16.919 billion in 2025, $16.125 billion in 2024, and $15.980 billion in 2023, with operating income of $3.422 billion , $1.414 billion , and $945 million respectively.

The Intel Foundry segment develops new leading-edge semiconductor process technologies and advanced packaging technologies and provides manufacturing, assembly and test and advanced packaging capacity and design enablement solutions. Intel Foundry revenue was $17.826 billion in 2025, $17.317 billion in 2024, and $18.504 billion in 2023, with operating losses of $10.318 billion , $13.291 billion , and $7.083 billion respectively. The "all other" category, which includes Mobileye, IMS, and Altera (through September 11, 2025), had revenue of $3.563 billion in 2025, $3.601 billion in 2024, and $5.463 billion in 2023, with operating income (loss) of $264 million , $(57) million , and $1.507 billion respectively.

In 2025, Intel completed several significant operational developments. On September 12, 2025, the company completed the divestiture of 51% of Altera for net purchase consideration of $4.3 billion , consisting of $4.8 billion in cash proceeds, $500 million in deferred cash proceeds, and offsets including $400 million for cash transferred to Altera and approximately $469 million in separation and employee-related costs. On August 27, 2025, Intel entered into a U.S. Government Agreement with the Department of Commerce, receiving $5.7 billion in accelerated CHIPS Act disbursements and issuing 275 million shares of common stock, a warrant to purchase up to 241 million shares at $20.00 per share, and 159 million Escrowed Shares. Intel also completed private placements with SoftBank Group for 87 million shares at $23.00 per share for $2.0 billion and with NVIDIA for 215 million shares at $23.28 per share for $5.0 billion . The company initiated the 2025 Restructuring Plan, recognizing restructuring charges of $2.2 billion in 2025, and reduced its core Intel workforce by approximately 15% by the end of fiscal 2025 compared to Q2 2025 ending headcount.

For fiscal year 2025, Intel reported net revenue of $52.853 billion , compared to $53.101 billion in 2024 and $54.228 billion in 2023. Gross profit was $18.375 billion in 2025, up from $17.345 billion in 2024, with gross margin of 34.8% versus 32.7% in the prior year. Operating loss was $2.214 billion in 2025, compared to an operating loss of $11.678 billion in 2024. Net income attributable to Intel was a loss of $267 million in 2025, compared to a loss of $18.756 billion in 2024 and income of $1.689 billion in 2023. Diluted loss per share attributable to Intel was $0.06 in 2025, compared to $4.38 in 2024 and earnings per share of $0.40 in 2023.

Business Outlook & Future Growth Drivers

The filing contains forward-looking statements regarding business plans and strategy, projections of future financial performance including future revenue, gross profits, capital expenditures and cash flows, but A primary growth vector is the revitalization of the x86 ecosystem, adapting and advancing x86 product offerings to support current and next-generation AI workloads. In 2025, Intel introduced its next generation client CPU code named Panther Lake, designed to combine improved power efficiency and performance to support next-generation AI-enabled workloads at the edge, and announced a strategic partnership with NVIDIA to co-develop custom client and data center products combining Intel's x86 CPU technologies with NVIDIA's AI and accelerated computing capabilities. The company expects Intel 18A, which first went into high-volume manufacturing in late 2025, to serve as the manufacturing process for multiple generations of future client and server CPU products, and is continuing development of Intel 14A, its next-generation node designed from inception as an offering to external customers.

Another major growth vector is the external foundry business, where Intel aims to leverage its U.S.-based capabilities in leading-edge semiconductor process technology R&D and manufacturing and advanced packaging to become a trusted foundry partner. Intel Foundry offerings include wafer fabrication, advanced packaging, chiplet integration and design enablement services. In 2025, Intel ramped Intel 18A into high-volume production and is seeking to establish it as the first significant node for government and enterprise foundry customers. The company is actively seeking customers for Intel 14A, but announced that if unable to secure a significant external foundry customer for Intel 14A, it may pause or discontinue its pursuit of next generation leading-edge process technologies, and in such event would expect over time to shift manufacturing to third-party foundries, particularly TSMC, as it develops products for nodes beyond Intel 18A and Intel 18A-P.

Intel is focused on margin and cost improvement through its enterprise-wide transformation. The 2025 Restructuring Plan is expected to result in total charges of approximately $2.2 billion , with a substantial majority of actions completed in Q4 2025 and the remainder expected to be completed in 2026. The company expects total R&D and MG&A expenses to decrease in 2026 relative to recent historical periods as a result of the 2025 and 2024 Restructuring Plans and other cost-reduction measures and the divestiture of Altera. In 2025, R&D expenses decreased by $2.8 billion , or 17% , from 2024, and MG&A expenses decreased by $883 million , or 16% , from 2024, primarily driven by lower payroll-related expenditures from headcount reductions.

Intel's operational outlook includes a more disciplined capital deployment strategy, better aligning new investments and key project milestones with market demand. In 2025, the company initiated the consolidation of its Costa Rican assembly and test operations into larger existing sites in Vietnam and Malaysia, expected to be completed by the end of 2026, slowed the pace of construction for its new Ohio wafer fabrication facility, and discontinued planned expansions in Germany (fab) and Poland (assembly and test facility). The company expects wafer fabrication supply constraints, primarily with respect to its Intel 7 and Intel 3 process nodes, to persist into 2026, with the most severe constraints impacting Q1 2026 , limiting its ability to fully meet customer demand. As of December 27, 2025, Intel had 85,100 people, and its undesired turnover rate was 7.9% in 2025.

Capital allocation priorities include continued investment in R&D and capital expenditures. R&D expenses were $13.8 billion in 2025, $16.5 billion in 2024, and $16.0 billion in 2023. Net purchases of property, plant and equipment (net capital expenditures) were $11.204 billion in 2025, $10.515 billion in 2024, and $23.228 billion in 2023. As of December 27, 2025, Intel had commitments for capital expenditures of $9.1 billion for 2026 and $3.7 billion in capital expenditures committed in the long term. The company has an ongoing authorization to repurchase shares, with $7.2 billion remaining available as of December 27, 2025, though no shares were repurchased during fiscal year 2025. No dividends were paid in 2025, compared to $1.599 billion in 2024 and $3.088 billion in 2023.

A significant headwind is the potential pause or discontinuation of Intel 14A and successor leading-edge process technologies if the company is unable to secure a significant external foundry customer. The filing states that if this occurs, Intel would expect over time to shift manufacturing to third-party foundries, particularly TSMC, and would face risks including dependence on third-party foundries, losses with respect to investments in R&D and manufacturing facilities, loss of eligibility for government incentives, potential penalty payments under SCIP agreements, and loss of talent. The company had over $100 billion of property, plant and equipment, net on its balance sheet as of December 27, 2025, the substantial majority of which relates to its foundry business.

Geopolitical tensions and trade policies present material constraints. Sales outside the U.S. accounted for 70% of revenue for fiscal year 2025, with revenue from billings to China contributing 24% of total revenue. The filing notes that geopolitical and trade tensions between the U.S. and China have led to increased tariffs and trade restrictions, and that the U.S. has imposed restrictions on the export of U.S.-regulated products and technology to certain Chinese technology companies. Additionally, the company faces risks from tensions and conflict affecting Israel and the Middle East, where it has a leading-edge fabrication facility and multiple product development centers, and from rising tensions between mainland China and Taiwan, where many of its products depend on suppliers for critical components.

Major Risk Factors & Challenges

Intel faces intense competition across its product portfolio, having lost market share in recent years in both client and data center markets, and its data center business has been negatively impacted by the significant shift of customer spend toward GPUs optimized for AI workloads where Intel has been unsuccessful to date in becoming a meaningful participant. The company's external foundry strategy is highly risky and uncertain, with limited experience in the capital-intensive third-party foundry business and few external customers to date. If Intel is unable to secure a significant external foundry customer for Intel 14A, it may pause or discontinue its pursuit of next generation leading-edge process technologies, which would subject it to significant strategic, financial, and operational risks including dependence on third-party foundries like TSMC and potential material impairments on its over $100 billion of property, plant and equipment. The company's significant debt obligations of $46.585 billion in aggregate principal amount of senior unsecured notes and other borrowings, combined with a credit rating downgrade from BBB+ to BBB in August 2025, could affect future borrowing costs and access to capital markets. Geopolitical tensions, particularly between the U.S. and China where China contributed 24% of total revenue, and conflicts affecting Israel where Intel has a leading-edge fabrication facility, present material risks to operations and financial results.

Management Priorities & Sentiments

Management's message emphasizes an enterprise-wide transformation to strengthen execution, enhance innovation, and better position Intel's products and offerings in a complex, highly competitive and rapidly evolving technology landscape. The strategy is centered on four core priorities: transforming the culture to become an engineering-focused, customer-centric organization; revitalizing the x86 ecosystem; growing the external foundry business; and expanding market opportunities by developing purpose-built ASICs and GPUs. Management states that if the company is unable to secure a significant external foundry customer for Intel 14A, it may pause or discontinue its pursuit of Intel 14A and successor leading-edge process technologies, and in such event would expect over time to shift manufacturing to third-party foundries, particularly TSMC. The filing notes that the company expects supply constraints to persist into 2026, with the most severe constraints impacting Q1 2026 , limiting its ability to fully meet customer demand, and that total R&D and MG&A expenses are expected to decrease in 2026 relative to recent historical periods.

References

  1. [1] Item 7, MD&A — Operating Segment Results / Note 3: Operating Segments
  2. [2] Item 7, MD&A — Operating Segment Results / Note 3: Operating Segments
  3. [3] Item 7, MD&A — Operating Segment Results / Note 3: Operating Segments
  4. [4] Item 7, MD&A — Operating Segment Results
  5. [5] Item 7, MD&A — Operating Segment Results
  6. [6] Item 7, MD&A — Operating Segment Results
  7. [7] Item 7, MD&A — Operating Segment Results
  8. [8] Item 7, MD&A — Operating Segment Results
  9. [9] Item 7, MD&A — Operating Segment Results
  10. [10] Item 7, MD&A — Operating Segment Results
  11. [11] Item 7, MD&A — Operating Segment Results
  12. [12] Item 7, MD&A — Operating Segment Results
  13. [13] Item 7, MD&A — Operating Segment Results
  14. [14] Item 7, MD&A — Operating Segment Results
  15. [15] Item 7, MD&A — Operating Segment Results
  16. [16] Item 7, MD&A — Operating Segment Results
  17. [17] Item 7, MD&A — Operating Segment Results
  18. [18] Item 7, MD&A — Operating Segment Results
  19. [19] Item 7, MD&A — Operating Segment Results
  20. [20] Item 7, MD&A — Operating Segment Results
  21. [21] Item 7, MD&A — Operating Segment Results
  22. [22] Item 7, MD&A — Operating Segment Results
  23. [23] Item 7, MD&A — Operating Segment Results
  24. [24] Item 7, MD&A — Operating Segment Results
  25. [25] Item 7, MD&A — Operating Segment Results
  26. [26] Item 7, MD&A — Operating Segment Results
  27. [27] Item 7, MD&A — Operating Segment Results
  28. [28] Item 7, MD&A — Significant Events and Trends / Note 10: Acquisitions and Divestitures
  29. [29] Item 7, MD&A — Significant Events and Trends / Note 10: Acquisitions and Divestitures
  30. [30] Item 7, MD&A — Significant Events and Trends / Note 10: Acquisitions and Divestitures
  31. [31] Item 7, MD&A — Significant Events and Trends / Note 10: Acquisitions and Divestitures
  32. [32] Item 7, MD&A — Significant Events and Trends / Note 10: Acquisitions and Divestitures
  33. [33] Item 7, MD&A — Significant Events and Trends / Note 5: Earnings Per Share and Stockholders' Equity
  34. [34] Item 7, MD&A — Significant Events and Trends / Note 5: Earnings Per Share and Stockholders' Equity
  35. [35] Item 7, MD&A — Significant Events and Trends / Note 5: Earnings Per Share and Stockholders' Equity
  36. [36] Item 7, MD&A — Significant Events and Trends / Note 5: Earnings Per Share and Stockholders' Equity
  37. [37] Item 7, MD&A — Significant Events and Trends / Note 5: Earnings Per Share and Stockholders' Equity
  38. [38] Item 7, MD&A — Significant Events and Trends / Note 5: Earnings Per Share and Stockholders' Equity
  39. [39] Item 7, MD&A — Significant Events and Trends / Note 5: Earnings Per Share and Stockholders' Equity
  40. [40] Item 7, MD&A — Significant Events and Trends / Note 5: Earnings Per Share and Stockholders' Equity
  41. [41] Item 7, MD&A — Significant Events and Trends / Note 5: Earnings Per Share and Stockholders' Equity
  42. [42] Item 7, MD&A — Significant Events and Trends / Note 5: Earnings Per Share and Stockholders' Equity
  43. [43] Item 7, MD&A — Significant Events and Trends / Note 5: Earnings Per Share and Stockholders' Equity
  44. [44] Item 7, MD&A — Restructuring / Note 7: Restructuring and Other Charges
  45. [45] Item 7, MD&A — Restructuring
  46. [46] Item 7, MD&A — Consolidated Results of Operations
  47. [47] Item 7, MD&A — Consolidated Results of Operations
  48. [48] Item 7, MD&A — Consolidated Results of Operations
  49. [49] Item 7, MD&A — Consolidated Results of Operations
  50. [50] Item 7, MD&A — Consolidated Results of Operations
  51. [51] Item 7, MD&A — Consolidated Results of Operations
  52. [52] Item 7, MD&A — Consolidated Results of Operations
  53. [53] Item 7, MD&A — Consolidated Results of Operations
  54. [54] Item 7, MD&A — Consolidated Results of Operations
  55. [55] Item 7, MD&A — Consolidated Results of Operations
  56. [56] Item 7, MD&A — Consolidated Results of Operations
  57. [57] Item 7, MD&A — Consolidated Results of Operations
  58. [58] Item 7, MD&A — Consolidated Results of Operations
  59. [59] Item 7, MD&A — Consolidated Results of Operations
  60. [60] Item 7, MD&A — Consolidated Results of Operations
  61. [61] Item 7, MD&A — Restructuring / Note 7: Restructuring and Other Charges
  62. [62] Item 7, MD&A — Consolidated Results of Operations
  63. [63] Item 7, MD&A — Consolidated Results of Operations
  64. [64] Item 7, MD&A — Consolidated Results of Operations
  65. [65] Item 7, MD&A — Consolidated Results of Operations
  66. [66] Item 7, MD&A — Operating Segment Results
  67. [67] Item 1, Business — People
  68. [68] Item 1, Business — People
  69. [69] Item 7, MD&A — Consolidated Results of Operations
  70. [70] Item 7, MD&A — Consolidated Results of Operations
  71. [71] Item 7, MD&A — Consolidated Results of Operations
  72. [72] Item 7, MD&A — Liquidity and Capital Resources
  73. [73] Item 7, MD&A — Liquidity and Capital Resources
  74. [74] Item 7, MD&A — Liquidity and Capital Resources
  75. [75] Item 7, MD&A — Liquidity and Capital Resources
  76. [76] Item 7, MD&A — Liquidity and Capital Resources
  77. [77] Item 5, Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
  78. [78] Item 7, MD&A — Liquidity and Capital Resources / Note 5: Earnings Per Share and Stockholders' Equity
  79. [79] Item 7, MD&A — Liquidity and Capital Resources / Note 5: Earnings Per Share and Stockholders' Equity
  80. [80] Item 1A, Risk Factors
  81. [81] Item 1A, Risk Factors
  82. [82] Item 1A, Risk Factors
  83. [83] Item 1A, Risk Factors
  84. [84] Item 7, MD&A — Liquidity and Capital Resources / Note 13: Borrowings
  85. [85] Item 1A, Risk Factors
  86. [86] Item 7, MD&A — Operating Segment Results
  87. [87] Item 8, Consolidated Statements of Operations
  88. [88] Item 8, Consolidated Statements of Operations
  89. [89] Item 8, Consolidated Statements of Operations
  90. [90] Item 8, Consolidated Statements of Operations
  91. [91] Item 8, Consolidated Statements of Operations
  92. [92] Item 8, Consolidated Statements of Operations
  93. [93] Item 8, Consolidated Statements of Operations
  94. [94] Item 8, Consolidated Statements of Operations
  95. [95] Item 8, Consolidated Statements of Operations
  96. [96] Item 8, Consolidated Statements of Operations
  97. [97] Item 8, Consolidated Statements of Operations
  98. [98] Item 7, MD&A — Consolidated Results of Operations
  99. [99] Item 7, MD&A — Consolidated Results of Operations
  100. [100] Item 8, Consolidated Statements of Operations
  101. [101] Item 8, Consolidated Statements of Operations
  102. [102] Item 8, Consolidated Statements of Cash Flows
  103. [103] Item 8, Consolidated Statements of Cash Flows
  104. [104] Item 7, MD&A — Liquidity and Capital Resources
  105. [105] Item 7, MD&A — Liquidity and Capital Resources
  106. [106] Item 7, MD&A — Liquidity and Capital Resources
  107. [107] Item 7, MD&A — Liquidity and Capital Resources
  108. [108] Item 7, MD&A — Liquidity and Capital Resources
  109. [109] Item 7, MD&A — Liquidity and Capital Resources
  110. [110] Item 7, MD&A — Significant Events and Trends / Note 10: Acquisitions and Divestitures
  111. [111] Item 7, MD&A — Consolidated Results of Operations / Note 5: Earnings Per Share and Stockholders' Equity
  112. [112] Item 7, MD&A — Restructuring / Note 7: Restructuring and Other Charges
  113. [113] Item 7, MD&A — Restructuring / Note 6: Other Financial Statement Details
  114. [114] Item 7, MD&A — Restructuring / Note 11: Goodwill
  115. [115] Item 7, MD&A — Consolidated Results of Operations / Note 8: Income Taxes
  116. [116] Item 7, MD&A — Operating Segment Results
  117. [117] Item 7, MD&A — Operating Segment Results
  118. [118] Item 7, MD&A — Operating Segment Results
  119. [119] Item 7, MD&A — Operating Segment Results
  120. [120] Item 7, MD&A — Operating Segment Results
  121. [121] Item 7, MD&A — Operating Segment Results

Report on Jun 8, 2026